custom image

Joint meeting with Hepatobiliary Cancers: Pathobiology and Translational Advances

Fatty Liver Disease and Multi-System Complications

March 22-24, 2021 | 10:00AM EDT | 2:00PM UTC | 3:00PM CET*
*Program is in development and subject to change


The live portion of this conference has concluded and all presentations are now available for purchase on demand. Registrants to the live event may access this content anytime for up to 9 months following the event.

 Free Access to On Demand Content to Scientists from Low-and Middle-Income Countries

Keystone Symposia welcomes the global scientific community and aims to connect researchers within and across disciplines to accelerate the advancement of biomedical and life sciences. This form may be used for scientists from low- and middle-income countries of all career stages to determine eligibility and request free access to scientific content presented during recent eSymposia events. If eligible, you will be sent an access code for the On Demand content of the eSymposia event(s) of interest.

Apply Here

The frequency of nonalcoholic fatty liver disease (NAFLD) has risen worldwide in parallel with the obesity epidemic; however, there are still no approved therapies. The more advanced form of the disease, non-alcoholic steatohepatitis (NASH), is associated with progressive fibrosis and an increased risk of hepatocellular carcinoma (HCC). In the last decade, genetic studies have identified new proteins that participate not only in the development of hepatic steatosis, but also disease progression to NASH, cirrhosis, and HCC. Meanwhile, research is starting to emerge describing underlying molecular pathways that mediate alterations in lipid and glucose metabolism, which leads to fat accumulation in liver. Therefore, the goals of this conference are to: 1) Explore the genetic contributions to NAFLD, and how these insights might reveal the sequence of events that cause NASH and cirrhosis; 2) Clarify the key molecular events in NAFLD and NASH, focusing on pathways that might provide therapeutic opportunities; and 3) Highlight emerging therapies for NASH. This conference comes at an opportunistic time, when several clinical trials are scheduled to conclude, providing critical data to enable scientists to refine research strategies for the future.

Apply Here for Free On Demand Access


Regular Registration Rate: $275 USD
Student Registration Rate: $150 USD


Abstract Submission:
‣ For Short Talk Consideration: Passed
‣ For Poster Booth: Passed
ePoster / SciTalk Submission: Passed
Financial Aid Application: Passed

*Abstract submission is required in order to submit an ePoster and/or Scitalk


Program Details

Keynote Speakers

custom image

Helen H. Hobbs
University of Texas Southwestern Medical Center

custom image

Hashem B. El-Serag
Baylor College of Medicine

Speaking at this eSymposia

Noura S. Abul-Husn

Icahn School of Medicine at Mount Sinai, USA

Kendra K. Bence

Pfizer Inc., USA

Morris J. Birnbaum

Pfizer Inc., USA

Chuhan Chung

Gilead Sciences, USA

Eran Elinav

Weizmann Institute of Science, Israel

Hashem B. El-Serag

Baylor College of Medicine, USA

Henry N. Ginsberg

Columbia University College of Physicians and Surgeons, USA

Daniel A. Heller

Memorial Sloan Kettering Cancer Center, USA

Helen H. Hobbs

University of Texas Southwestern Medical Center, USA

Jay D. Horton

University of Texas Southwestern Medical Center, USA

Mitchell A. Lazar

Perelman School of Medicine, University of Pennsylvania, USA

Lei Ling

NGM Biopharmaceuticals, USA

Mark A. McNiven

Mayo Clinic, USA

Lopa Mishra

George Washington University, USA

Catherine Postic

INSERM, Institut Chochin, France

Maria Rescigno

Humanitas University, Italy

Alphonse E. Sirica

Virginia Commonwealth University, USA

Elizabeth K. Speliotes

University of Michigan, USA

Greg Steinberg

McMaster University, Canada

Tobias C. Walther

Harvard School of Public Health, USA

Hannele Yki-Järvinen

University of Helsinki, Finland




Additional Support



Funding for this conference was made possible (in part) by 1 R13 DK 129023-01 from NIDDK. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and

Media-in-Kind Support











This new virtual meeting format came out of difficult circumstances, but your commitment to scientific progress is what inspired us to launch Keystone eSymposia. In these virtual meetings, we are capturing the same innovative essence of our in-person meetings that you've all created as a scientific community. Here, Debbie Johnson, our CEO, explains how we're going to do that.

The views expressed in this eSymposia are those of the participants and not necessarily of the participants’ organizations or of Keystone Symposia.

Donate to Keystone Symposia

custom image